12 results about "Tumour therapy" patented technology

Provided is a method of oncolytic virus therapy for a tumour based on using neutrophil count as a predictor of the efficacy of oncolytic virus therapy for the tumour, comprising: determining the neutrophil count level in the blood of a tumour patient prior to tumour treatment; and, when the neutrophil count level in the blood of the tumour patient is below a cut-off value, administering an oncolytic virus to the tumour patient for treatment, wherein the cut-off value is any value from 2×109 to 5.5×109 / L.

A pharmaceutical combination product including:a liposomal formulation consisting of one or more liposomes each encapsulating a bacterial lipopolysaccharide (LPS) as a single active ingredient; andat least one anti-tumor compound chosen from the group consisting of: a therapeutic antibody, a chemotherapy agent, and an immunotherapy agent.Methods for treating a tumor comprising administering to a patient having said tumor an effective amount of said pharmaceutical combination product.

Alternating electric fields (e.g., TTFields) may be applied to the body of a subject using one or more electrode assemblies including a sheet of anisotropic material, at least one conductive material layer disposed on a front surface of the sheet of anisotropic material, and an electrode element disposed behind the sheet of anisotropic material. The electrode element has a front surface disposed in electrical contact with a rear surface of the sheet of anisotropic material. The sheet of anisotropic material spreads both heat and current in a direction parallel to the front surface of the sheet, eliminating or at least minimizing hot spots on the electrode assembly. This in turn allows for increased current flow without exceeding a temperature safety threshold (e.g., 41°C).

The invention relates to the technical field of tumor treatment, in particular to a VEGFR-2 / BRD4 double-target inhibitor and application thereof. The structural general formula of the VEGFR-2 / BRD4 double-target inhibitor is as shown in a formula I in the specification. The tetrahydropteridine compound containing the aryl amide or aryl urea structure, disclosed by the invention, has relatively strong inhibitory activity on VEGFR-2 / BRD4 activity; according to the present invention, the VEGFR-2 / BRD4 double-target inhibitor has good anti-proliferative activity on tumor cells, the compound I-5 shows the optimal activity, and the activity is far superior to the positive control Sorafenib, ReGrafenib and JQ-1, the effect of the ReGrafenib and the effect of the combination of the Sorafenib and the JQ-1 respectively, and the target treatment drug for leukemia, gastrointestinal stromal tumor, liver cancer, kidney cancer, thyroid cancer, non-small cell lung cancer, colorectal cancer and the like can be prepared, and the compound I-5 can be used for the preparation of the target treatment drug for treating leukemia, gastrointestinal stromal tumor, liver cancer, kidney cancer, thyroid cancer, non-small cell lung cancer, colorectal cancer and the like.

The present application relates to the field of tumor treatment, and particularly relates to a combination of a selective VEGFR3 inhibitor and an anti-PD-L1 antibody and application thereof in lung cancer treatment.

The invention belongs to the technical field of biological medicines, and particularly relates to application of mouse T lymphocyte-derived extracellular vesicles in treatment or relief of colorectal cancer. The extracellular vesicles are derived from cytotoxic T lymphocyte line 2 (Cytotoxic T Lympholyte Line 2, CTLL2), and the CTLL2-derived extracellular vesicles extracted by using an exosome extraction kit after a differential centrifugation method can effectively influence the biological functions of colorectal cancer cell lines, inhibit the growth of colorectal cancer tumors and reduce the death rate of colorectal cancer model mice. In addition, the extracellular vesicles have no injury effect on important organs such as heart, liver, spleen, lung, kidney and the like of a mouse; results show that the extracellular vesicles derived from mouse T lymphocytes have a good effect in the aspect of colorectal cancer treatment and show application potential in the field of tumor treatment.